From the Journals

ICYMI: Durvalumab boosts overall survival in stage III NSCLC


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Patients with unresectable stage III non–small cell lung cancer who received durvalumab had their overall and progression-free survival boosted by about 12 months, compared with patients who received a placebo, according to results of the multicenter, randomized, double-blind, placebo-controlled, phase 3 PACIFIC trial published in the New England Journal of Medicine (2018 Sep 25. doi: 10.1056/NEJMoa1809697).

We covered this story at the World Conference on Lung Cancer before it was published in the journal. Find our coverage at the link below.

Next Article: